Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30593827 | 0.83 | GPBAR1 (0.75) | TP53GPBAR1LMNATSHRADORA2B | |
| SCHEMBL17478026 | 0.83 | TP53 (0.62) | TP53GPBAR1LMNATSHRALOX15 | |
| SCHEMBL31705784 | 0.81 | MAPK1 (1.00) | MAPK1LMNATSHRADORA2BKDM4E | |
| SCHEMBL3016247 | 0.80 | MAPK1 (0.70) | TP53MAPK1LMNATSHRKDM4E | |
| SCHEMBL16421866 | 0.80 | TSHR (0.69) | TP53GPBAR1LMNATSHRALOX15 | |
| SCHEMBL17478023 | 0.77 | GPBAR1 (1.00) | TP53GPBAR1LMNA | |
| SCHEMBL3885661 | 0.77 | GPBAR1 (0.71) | TP53GPBAR1TSHRALOX15MAPT | |
| SCHEMBL31706021 | 0.77 | MAPK1 (0.79) | MAPK1LMNATSHRADORA2BMEN1 | |
| SCHEMBL17484678 | 0.75 | GPBAR1 (0.60) | TP53GPBAR1LMNATSHRALOX15 | |
| SCHEMBL17782167 | 0.75 | TP53 (0.56) | TP53GPBAR1LMNATSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2433634-A2 | Compounds, compositions and methods of inhibiting a-synuclein toxicity | The Whitehead Institute for Biomedical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1802303-B1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INHIBITING A-SYNUCLEIN TOXICITY | WHITEHEAD BIOMEDICAL INST (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2007089548-A2 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | SNCA, PARK7, HTT | TP53 1529/4885MAPK1 2847/4885GPBAR1 3453/4885 |
| US-20100004277-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | TP53 3445/4885MAPK1 1965/4885GPBAR1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.